CDC42 and central nervous system cancer: While tofacitinib and S3I‐201 did not affect basic levels of Cdc42 protein, both inhibitors blocked the upregulation of Cdc42 in response to CTRP8 treatment in human glioma cells (Fig. 1A,C,E).